CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC).

芝加哥--（商业新闻短讯）--人工智能和精准医学领域的领导者Tempus今天宣布扩大与阿斯利康的合作，阿斯利康利用Tempus Next武装医生的技术，支持为非小细胞肺癌（NSCLC）患者提供指导性生物标志物检测。

The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly incorporated into patient treatment plans. As part of a larger, strategic collaboration, the two companies are now expanding upon a pilot program that utilizes Next, Tempus’ care pathway intelligence platform, to help physicians determine if their patients with NSCLC may benefit from guideline-directed molecular testing, including testing for epidermal growth factor receptor (EGFR) mutations..

每年更新肿瘤学指南的规模和频率使得更新很难迅速纳入患者治疗计划。作为一项规模更大的战略合作的一部分，两家公司目前正在扩大一项试点项目，该项目利用Next，Tempus的护理路径智能平台，帮助医生确定他们的非小细胞肺癌患者是否可以从指南指导的分子检测中受益，包括表皮生长因子受体（EGFR）突变检测。。

EGFR is a biomarker that presents in some patients with NSCLC and that has specific targeted therapies associated with it. Currently, ~30-40% of eligible NSCLC patients do not receive appropriate testing1. In September 2023, Tempus and AstraZeneca initiated a pilot program to leverage Next to identify this specific care gap at participating provider sites, using AI to scan unstructured clinical data to understand which patients may be eligible for testing based on clinical guidelines, and notifying treating physicians to inform care.

EGFR是一种生物标志物，存在于一些NSCLC患者中，并具有与之相关的特异性靶向治疗。目前，约30-40%的符合条件的NSCLC患者未接受适当的检测1。2023年9月，Tempus和AstraZeneca启动了一项试点计划，利用Next来确定参与提供者网站的这一特定护理差距，使用人工智能扫描非结构化临床数据，以了解哪些患者可能有资格根据临床指南进行检测，并通知治疗医生告知护理。

The pilot’s initial success within the first six months prompted a new expansion of the program to support deployment of the care pathway model in a total of 15 provider sites..

该试点在前六个月内取得的初步成功促使该计划进行了新的扩展，以支持在总共15个提供者站点部署护理路径模型。。

“Next was designed to ensure all patients have access to treatment plans based on the most up-to-date guidelines by equipping physicians with cutting-edge tools in their existing workflows to support the delivery of evidence-based care,” said Chris Scotto DiVetta, Senior Vice President, AI Applications at Tempus.

Tempus人工智能应用高级副总裁克里斯·斯科托·迪维塔（ChrisScottoDivetta）表示：“Next旨在确保所有患者都能获得基于最新指南的治疗计划，为医生提供现有工作流程中的尖端工具，以支持循证护理的提供。”。

“We were excited to see initial success in this program and look forward to contributing to a future where advanced technology and medical expertise unite to improve outcomes for all patients.”.

“我们很高兴看到这个项目取得了初步成功，并期待着为未来做出贡献，让先进技术和医学专业知识联合起来，改善所有患者的预后。”。

Tempus Next is designed to accelerate the adoption of precision medicine and enhance patient outcomes. The solution integrates seamlessly with EMRs in order to analyze a comprehensive suite of data—including clinical notes, molecular information, and imaging—to pinpoint certain deviations from care guidelines.

Tempus Next旨在加速精准医学的采用并提高患者的治疗效果。该解决方案与EMR无缝集成，以便分析一整套数据，包括临床笔记，分子信息和成像，以查明与护理指南的某些偏差。

Participating health systems receive regular updates, supporting guideline-directed care for their patients. To learn more, visit tempus.com/oncology/care-pathway-solution..

参与的卫生系统定期接受更新，为患者提供指导性护理。要了解更多信息，请访问tempus.com/oncology/care-pathway-solution。。

1 Sadik H, Pritchard D, Keeling DM, et al. Impact of Clinical Practice Gaps on the Implementation of Personalized Medicine in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022;6:e2200246. doi:10.1200/PO.22.00246

1 Sadik H，Pritchard D，Keeling DM等。临床实践差距对晚期非小细胞肺癌实施个性化医疗的影响。JCO Precis Oncol。2022年；6： e2200246。doi:10.1200/PO.22.00246

About Tempus

关于Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

Tempus是一家通过人工智能在医疗保健中的实际应用来推进精准医学的技术公司。Tempus拥有世界上最大的多模式数据库之一，并拥有一个可访问和有用的操作系统，为医生提供支持AI的精准医学解决方案，以提供个性化的患者护理，同时促进最佳治疗方法的发现，开发和交付。

The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com..

目标是通过为医生提供工具，让每位患者在公司收集更多数据时学习，从而从之前的其他患者的治疗中受益。有关更多信息，请访问tempus.com。。